Bromocriptine was reported to reduce hepatic lipid levels and insulin resistance, which are linked suppressed hyperleptinemia and inhibition of transcription factors and enzymes for lipogenesis and glucongeogenesis, as well as signaling proteins such as suppressor of cytokine signaling 3 (SOCS3), and Jun N-terminal kinase (JNK; Ezrokhi et al., 2014). This evidence concerns the gene MAPK8 and Insulin resistance.